Delivery Order SPE2DB22D2007-SPE2DB25FJ5LA
- Not listed
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $74,205.29. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made competitively without set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $35,816.58 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be executed from the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract represents a firm fixed price delivery order with a ceiling value of $38,113.45 and an ultimate completion date of September 15, 2025. This non-set-aside award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier to the federal government, with performance taking place...
- The Defense Logistics Agency awarded a $8,482.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of RINVOQ ER 15 MG tablets (30-count units). This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999 through December 2026. Performance will be completed by August 6, 2025, with...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a $25,160.03 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30 units). The contract is a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. Performance will be...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for RINVOQ ER 15mg tablets (30-count supply), with a ceiling value of $13,367.72. This firm fixed-price delivery order, with a completion date of September 16, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $34,710.69. This firm fixed-price delivery order represents a non-set-aside competitive award and is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,931.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor,...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5LADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $77,613.62. This non-set-aside competitive award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery order is September 29, 2025, with performance taking place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, continues to serve as a critical vendor for federal medical procurement through its extensive portfolio of pharmaceutical products and medical supplies. The company's DLA Troop Support contract serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of specialty medications, brand-name and generic drugs, vaccines, and other medical commodities to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for RINVOQ ER represents one of numerous competitively awarded transactions demonstrating AmerisourceBergen's capability to fulfill federal medical supply requirements across varying order values and therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $77.6k | 9/26/25 |